Patents by Inventor Christopher E. Williams
Christopher E. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932360Abstract: A tuned mass damper (TMD) system in combination with a floating offshore wind turbine (FOWT) platform includes a barge type FOWT platform having a hull configured to have a wind turbine tower mounted thereon. A TMD system is mounted in the hull and has a first TMD configured to operate at a first frequency, and a second TMD configured to operate at a second frequency different than the first frequency.Type: GrantFiled: November 4, 2019Date of Patent: March 19, 2024Assignee: University of Maine System Board of TrusteesInventors: Christopher K. Allen, Anthony M. Viselli, Andrew J. Goupee, Habib J. Dagher, Robert E. Berry, Jeffrey L. Lindner, Frederick S. Gant, John S. Townsend, Rebecca L. Williams
-
Patent number: 7304029Abstract: The invention relates to neuroprotection and to medicaments for use therein. Neuroprotection is induced by activation of neural growth hormone receptors, primarily using medicaments comprising growth hormone, growth hormone analogs or ligands which are functionally equivalent. Such medicaments may also include one or more secondary neuroprotective agents.Type: GrantFiled: September 3, 1999Date of Patent: December 4, 2007Assignee: Neuren Pharmaceuticals Ltd.Inventors: Arjan Scheepens, Christopher E. Williams, Peter David Gluckman, Ross Graham Clark
-
Patent number: 6812208Abstract: A method for treatment or prophylaxis of a patient suffering from functional symptoms of Parkinson's disease, especially as a consequence of damage to dopaminergic neurons, by administering to the patient a neuroprotective amount of a peptide selected from the tripeptide gly-pro-glu (GPE) and analogs and mimetics thereof, preferably GPE. The GPE will usually be administered subsequent to the onset of Parkinson's disease but prior to the damage of said dopaminergic neurons.Type: GrantFiled: May 24, 2001Date of Patent: November 2, 2004Assignee: NeuronZ Ltd.Inventors: Peter D. Gluckman, Christopher E. Williams, Jian Guan, Rita V. M. Krishnamurthi
-
Patent number: 6796941Abstract: An intelligent brain rescue instrument for identifying, monitoring, and guiding the application of brain therapies to patients with evolving brain injuries, comprises an input for acquiring a multiple number of signals each indicative of a different biochemical or biophysical parameter of a patient, and a computer to continuously sample each of the acquired signals and display to a user on a monitor at least some of the parameters. The displayed parameters are selected by system software embodying expert analytical rules as the most significant parameters, or as parameters having values indicative, or predictive at any time of actual, or potential future deterioration of the brain state of the patient.Type: GrantFiled: January 23, 2002Date of Patent: September 28, 2004Assignee: Tru-Test Corporation LimitedInventors: Christopher E. Williams, Mark I. Gunning
-
Use of GPE to protect glial cells or non-dopaminergic cells from death from neural injury or disease
Patent number: 6780848Abstract: The tripeptide glycine-proline-glutamine (GPE) may be administered before, or usually after, injury to reduce damage to the central nervous system. GPE appears useful for neuronal rescue particularly but not exclusively within the hippocampus. Advantages of GPE include: (a) that it crosses the blood-brain barrier, so is effective by injected peripheral administration, (b) it is unlikely to challenge the immune system, (c) it is cheap, and (d) its therapeutic ratio is high. GPE may also be infused into the CSF. It may be administered prior to parturition or elective brain or cardiac surgery. Transdermal routes may be useful for chronic neural disorders. The CNS of mammals (including foetal mammals) after trauma including hypoxic/ischaemic experimental insults showed reduced damage under GPE protection as measured by histological assessment of cell damage or death and regional shrinkage.Type: GrantFiled: July 20, 2001Date of Patent: August 24, 2004Assignee: NeuronZ, Ltd.Inventors: Peter D. Gluckman, Christopher E. Williams -
Publication number: 20020082514Abstract: An intelligent brain rescue instrument for identifying, monitoring, and guiding the application of brain therapies to patients with evolving brain injuries, comprises input means (101-103) for acquiring a multiple number of signals each indicative of a different biochemical or biophysical parameter of a patient, computing means (104-107) to continuously sample each of the acquired signals and display to a user on a monitor (109) at least some of the parameters, the displayed parameters being selected by system software embodying expert analytical rules as the most significant parameters, or as parameters having values indicative, or predictive at any time of actual, or potential future deterioration of the brain state of the patient.Type: ApplicationFiled: January 23, 2002Publication date: June 27, 2002Applicant: Auckland Uniservices LimitedInventors: Christopher E. Williams, Mark I. Gunning
-
Patent number: 6406427Abstract: An intelligent brain rescue instrument for identifying, monitoring, and guiding the application of brain therapies to patients with evolving brain injuries, includes an input for acquiring a multiple number of signals each indicative of a different biochemical or biophysical parameter of a patient, a computer to continuously sample each of the acquired signals and display to a user on a monitor at least some of the parameters, the displayed parameters being selected by system software embodying expert analytical rules as the most significant parameters, or as parameters having values indicative, or predictive at any time of actual, or potential future deterioration of the brain state of the patient.Type: GrantFiled: February 18, 2000Date of Patent: June 18, 2002Assignee: Auckland Uniservices LimitedInventors: Christopher E. Williams, Mark I. Gunning
-
Patent number: 6365573Abstract: This invention relates to the use of the tripeptide Gly-Pro-Glu (GPE) or analogs thereof for the treatment of conditions of the central nervous system (e.g. cerebral vasculitis) in which the amount of the neural enzymes nitric oxide synthetase (NOS) and/or glutamic acid decarboxylase (GAD) is reduced.Type: GrantFiled: May 10, 1999Date of Patent: April 2, 2002Assignee: Neuronz Ltd.Inventors: Peter D Gluckman, Christopher E. Williams, Jian Guan
-
Publication number: 20020035066Abstract: A method for treatment or prophylaxis of a patient suffering from functional symptoms of Parkinson's disease, especially as a consequence of damage to dopaminergic neurons, by administering to the patient a neuroprotective amount of a peptide selected from the tripeptide gly-pro-glu (GPE) and analogs and mimetics thereof, preferably GPE. The GPE will usually be administered subsequent to the onset of Parkinson's disease but prior to the damage of said dopaminergic neurons.Type: ApplicationFiled: May 24, 2001Publication date: March 21, 2002Inventors: Peter D. Gluckman, Christopher E. Williams, Jian Guan, Rita V.M. Krishnamurthi
-
Publication number: 20020013277Abstract: The tripeptide glycine-proline-glutamine (GPE) may be administered before, or usually after, injury to reduce damage to the central nervous system. GPE appears useful for neuronal rescue particularly but not exclusively within the hippocampus. Advantages of GPE include: (a) that it crosses the blood-brain barrier, so is effective by injected peripheral administration, (b) it is unlikely to challenge the immune system, (c) it is cheap, and (d) its therapeutic ratio is high. GPE may also be infused into the CSF. It may be administered prior to parturition or elective brain or cardiac surgery. Transdermal routes may be useful for chronic neural disorders. The CNS of mammals (including foetal mammals) after trauma including hypoxic/ischaemic experimental insults showed reduced damage under GPE protection as measured by histological assessment of cell damage or death and regional shrinkage.Type: ApplicationFiled: July 20, 2001Publication date: January 31, 2002Inventors: Peter D. Gluckman, Christopher E. Williams
-
Patent number: 6187906Abstract: Disclosed herein is a method for protecting dopaminergic neurons of a mammal against death resulting from Parkinson's disease. The method comprises administering a neuroprotective amount of the tripeptide Gly-Pro-Glu.Type: GrantFiled: June 15, 1999Date of Patent: February 13, 2001Assignee: Aukland Uniservices LimitedInventors: Peter D. Gluckman, Christopher E. Williams, Jian Guan